The Swiss nuclear medical imaging vendor Positrigo has completed a financing round valued at 7 million Swiss francs (€7.4 million).
With venture capital investors HealthCap and Navivo Capital in Europe, Positrigo plans to accelerate production of its functional brain imaging system NeuroLF and focus on commercial rollout in the U.S. and Europe. The dedicated brain PET system secured its Medical Device Regulation (MDR) certificate in Europe in October 2024, after clearance from the U.S. Food and Drug Administration (FDA) in July.
NeuroLF helps diagnose and monitor brain disorders such as Alzheimer's disease, tumors, epilepsy, and Parkinson's disease, allowing patients to undergo a brain scan in a seated position, according to Positrigo.
In its announcement, the company also noted the addition to its board of directors of HealthCap partner Max Odlander; Ajit Singh, PhD, of Artiman Ventures; and Didier Deltort, formerly of GE HealthCare.
